Two weeks. A bottle costing less than £22. A number big enough to stop the scroll. BYOMA’s new Longevit-8 Peptide Serum has arrived with the sort of wrinkle promise that deserves a second look—particularly at the words beside the percentage.
The UK product page says it can reduce visible wrinkle depth by up to 85% in two weeks. That is a claim about the depth of visible lines, not 85% fewer wrinkles, and not a promise that everyone will see that result. The listed price is £21.99 for 40ml, checked on 21 September. [1]
“Up to” leaves an important question unanswered: what happened to the typical participant? A maximum result and an average result can tell very different stories. We would want both, plus the range of outcomes, before treating the largest number as a useful shopping guide.
There is another question hiding inside “depth”. Was the change measured using an instrument, judged from standardised photographs, or assessed another way? How deep were the lines at the start? A percentage without its starting measurement does not tell you how noticeable the difference would be in a face-to-face conversation.
A headline result is not the same thing as your likely result.
BYOMA describes the benefit as clinically proven, but the UK product page and its accompanying claim graphic do not provide a participant count, a control comparison, an average wrinkle-depth change or the measurement protocol. We have not obtained the underlying report. That prevents an independent appraisal of this particular number; it does not establish that the serum is ineffective. [1]
Peptides themselves are not automatically marketing decoration. A published 2005 trial tested a moisturiser containing a particular peptide against the same moisturiser without it. It involved 93 women over 12 weeks, used a randomised split-face design and reported an improvement. The researchers were affiliated with Procter & Gamble. That is useful evidence about a specific preparation, with a commercial affiliation worth knowing—not proof for every peptide serum. [2]
Crucially, that study did not test this BYOMA formula or its two-week claim. Borrowing another product’s research would skip the very question we are asking: what does this finished bottle demonstrably do?
The longevity language deserves the same care. Looking smoother after a fortnight and preserving skin function over years are different propositions. A short-term appearance result cannot, on its own, demonstrate the latter. For a shopper, the useful question is less “does this sound advanced?” and more “which benefit was measured, against what, and for how long?”
Our reading is not verifiable from the public information reviewed. That grades the transparency of the evidence available to us, not the product’s quality. We would reconsider it if a study report supplied the missing detail.
At this price, the serum may still interest someone shopping for a new routine addition. But affordability is not evidence, any more than a luxury price is. You do not need to believe the biggest possible result to be curious about a product—and you do not need to buy a promise just because it comes with a percentage.
Sources & how we reported this
Desk-based claims analysis, checked 21 September 2026. We have not used or independently tested this serum, obtained its clinical report, or contacted BYOMA for comment. No brand response is implied. The next reporting step would be to request the participant count and demographics, comparison group, measurement method, average and maximum changes, variability, and full study report. Product photograph: BYOMA, served from the manufacturer’s website; not a results photograph. Product link is not an affiliate link.
- BYOMA UK: Longevit-8 Peptide Serum—manufacturer’s product description, price and accompanying claims graphic. Commercial source.
- Robinson et al., Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin, International Journal of Cosmetic Science (2005), 27:155–160. Different peptide preparation and study duration; not a trial of BYOMA.